PROCEDURE TO PREACH SENSITIVITY TO A PHARMACEUTICAL THERAPY FOR OBESITY.

摘要

A procedure for predicting treatment sensitivity for obesity or overweight in a human being with a pharmaceutical agent selected from the group consisting of a 5-HT2C receptor agonist, a cannabinoid-1 receptor antagonist (CB-1), an inhibitor of Phospholipid diesterase-10 (PDE-10), an orexin-1 antagonist, a triple serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), a lipase inhibitor and / or a lipid absorption receptor inhibitor , which comprises determining in a biomarker isolated from the human being if there is a reduction in the response of the lipoprotein particles rich in triglyceride subclass V6 (TRL V6) to a fat load in the presence of the pharmaceutical agent, compared to the TRL response V6 in the absence of the pharmaceutical agent, where the reduction in the response of TRL V6 indicates that the patient will be sensitive to treatment for obesity or overweight.